Neuren Pharmaceuticals : Notification regarding unquoted securities - NEU

For personal use only

Entity name

NEUREN PHARMACEUTICALS LIMITED

Date of this announcement

Thursday February 03, 2022

The +securities the subject of this notification are:

+Other securities issued under an +employee incentive scheme that are not intended to be quoted on ASX

Total number of +securities to be issued/transferred

Refer to next page for full details of the announcement

For personal use only

1.1 Name of entity

NEUREN PHARMACEUTICALS LIMITED

We (the entity named above) give notice of the issue, conversion or payment up of the following unquoted +securities.

1. The announcement is New announcement
2. Date of this announcement

3/2/2022

For personal use only

2.2a This notification is given in relation to an issue of +securities in a class which is not quoted on ASX and which:

does not have an existing ASX security code ("new class")

use only

Date the +securities the subject of this notification were issued

3/2/2022

Will all the +securities issued in this class rank equally in all respects from their issue date? Yes

Were any of the +securities issued to +key management personnel (KMP) or an +associate? Yes

personal

Provide details of the KMP or +associates being issued +securities.

Number of +securities

250,000

500,000

For

Have you received confirmation from ASX that the terms of the +securities are appropriate and equitable under listing rule 6.1?

No

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities being issued.

Material terms:

• Exercise price ($3.46 per share) is the volume weighted average price (VWAP) at which the Company's shares were traded on the ASX in the 5 days preceding the date of issue of the Options.
• Vested options may be exercised no earlier than 1 year after the issue date.
• All options lapse 4 years after the issue date.
• Options are subject to the following vesting conditions:

1. when the Company determines to progress NNZ-2591 to a Phase 2b or Phase 3 clinical trial following a positive Phase 2 clinical trial outcome, or executes a partnering transaction for NNZ-2591;
2. when the Company executes a partnering transaction for trofinetide outside North America, or submits a Marketing Authorisation Application for trofinetide in the European Union, the United Kingdom or Japan.
3. on acceptance by the US FDA of the filing of a New Drug Application for trofinetide.

- The options carry no entitlement to vote or participate in new issues.

For personal

Number of +securities 1,450,000